India

Bayer to force India patients to pay monopolistic prices for its drugs

Friday, March 08, 2013 by: J. D. Heyes
Tags: Bayer, India, monopoly prices

eTrust Pro Certified

Most Viewed Articles
Popular on Facebook
The five biggest lies about Ebola being pushed by government and mass media
Why does the CDC own a patent on Ebola 'invention?'
White House admits staging fake vaccination operation to gather DNA from the public
Ultraviolet light robot kills Ebola in two minutes; why doesn't every hospital have one of these?
EXCLUSIVE: Natural News tests flu vaccine for heavy metals, finds 25,000 times higher mercury level than EPA limit for water
Truvia sweetener a powerful pesticide; scientists shocked as fruit flies die in less than a week from eating GMO-derived erythritol
Irrefutable proof we are all being sprayed with poison: 571 tons of toxic lead 'chemtrailed' into America's skies every year
Tetanus vaccines found spiked with sterilization chemical to carry out race-based genocide against Africans
Russia taking McDonald's to court, threatens countrywide shutdown
Oregon man serving prison sentence for collecting rainwater on his own property
The best way to help your body protect itself against Ebola (or any virus or bacteria)
Global warming data FAKED by government to fit climate change fictions
Senator who attacked Doctor Oz over dietary supplements received over $146,000 in campaign contributions from Big Pharma mega-retailer and Monsanto
Healthy 12-year-old girl dies shortly after receiving HPV vaccine
Ebola outbreak may already be uncontrollable; Monsanto invests in Ebola treatment drug company as pandemic spreads
HOAX confirmed: Michelle Obama 'GMOs for children' campaign a parody of modern agricultural politics
Ben & Jerry's switches to non-GMO, Fair Trade ice cream ingredients
W.H.O. contradicts CDC, admits Ebola can spread via coughing, sneezing and by touching contaminated surfaces

Delicious
(NaturalNews) What does virtually every multinational corporation adore? Answer: A monopoly on its products. Less or no competition, you see, means higher profits and without regard to consumers' pocketbooks.

That might be one reason to explain why German Big Pharma corporation Bayer has said it will challenge a decision by Indian officials to allow production of a cheaper generic copy of its patented cancer drug.

The decision came after India last year agreed to allow Natco Pharma to produce the drug Nexavar. On March 4, the Indian patent appeal's office rejected Bayer's bid to overturn that ruling, to which the company said it "strongly" disagreed and would appeal to the high court in Mumbai.

Research is expensive, but theft or counterfeiting is worse

The BBC reported that Bayer sells the drug for 280,000 rupees ($5,118) for a 120-tablet pack - expensive, by any estimation.

"Bayer is committed to protecting its patents for Nexavar and will rigorously continue to defend our intellectual property rights within the Indian legal system," the company said in a statement, which was quoted by The Associated Press.

And while acknowledging that research and development is both necessary and expensive, health groups have nonetheless applauded the Indian decision because they know that if allowed to stand, it will lead to more affordable versions of previously patented medications.

"The decision means that the way has been paved for compulsory licenses to be issued on other drugs, now patented in India and priced out of affordable reach, to be produced by generic companies and sold at a fraction of the price," said Leena Menghaney, of the medical charity Medecins Sans Frontieres, according to BBC.

The Nexavar case is the first one in India where a company has been granted a "compulsory license" to manufacture a patented drug. Under the ruling, Natco must pay seven percent of its royalties to Bayer as compensation.

The decision comes as the pharmaceutical industry is exploding in India, a burgeoning nation of more than 1.2 billion people, many of which still live in abject poverty. The industry there is worth $12 billion annually and is expected to grow four-fold over the next 10 years.

But the country also has a serious problem; it is increasingly inundated with phony medications.

Phony drugs a bigger problem than cheaper alternatives for real drugs

Writing in The Wall Street Journal in May 2010, Roger Bate, a senior fellow at the American Enterprise Institute, said Indian authorities were cracking down on phony pharmaceuticals but that the problem was daunting: During a series of raids, agents with India's Food and Drug Administration of the Indian State of Uttar Pradesh uncovered large quantities of substandard medicines which resulted in several arrests:

This evidence of India's fake drug trade jibes with what I've found in several surveys. In 2009, I looked at five important medicines being sold at 52 different pharmacies in Delhi and Chennai, using covert shoppers. In Dehli, 12 percent of the pills were substandard, as were five percent in Chennai. About two percent of the pills contained no active ingredient. The others did but it had degraded, probably because the pills had expired and been repackaged with new labels; some may have degraded through poor storage.

Because of the enormity of the country and its population, coupled with far less regulatory oversight than here in the U.S., estimates of just how big the problem really is vary wildly. The BBC reported that up to a quarter of the medicines "consumed in poor countries could be counterfeit or substandard, according to the World Health Organization."

It's big business. Counterfeit drugs - in which no royalties are paid to patent-holders, by the way, amount to about $200 billion annually worldwide. What's more, "producers need very little inventory to set up the manufacturing process and can make huge profits."

This problem is especially worrisome to Indian officials.

"With manufacturing costs nearly 40 percent cheaper than other countries, the authorities are worried India could become an easy target for counterfeiters," said BBC.

Sources:

http://www.bbc.co.uk/news/world-asia-india-21665598

http://online.wsj.com

http://www.washingtonpost.com

Join over four million monthly readers. Your privacy is protected. Unsubscribe at any time.
comments powered by Disqus
Take Action: Support NaturalNews.com by linking back to this article from your website

Permalink to this article:

Embed article link: (copy HTML code below):

Reprinting this article:
Non-commercial use OK, cite NaturalNews.com with clickable link.

Follow Natural News on Facebook, Twitter, Google Plus, and Pinterest

Colloidal Silver

Advertise with NaturalNews...

Support NaturalNews Sponsors:

Advertise with NaturalNews...

GET SHOW DETAILS
+ a FREE GIFT

Sign up for the FREE Natural News Email Newsletter

Receive breaking news on GMOs, vaccines, fluoride, radiation protection, natural cures, food safety alerts and interviews with the world's top experts on natural health and more.

Join over 7 million monthly readers of NaturalNews.com, the internet's No. 1 natural health news site. (Source: Alexa.com)

Your email address *

Please enter the code you see above*

No Thanks

Already have it and love it!

Natural News supports and helps fund these organizations:

* Required. Once you click submit, we will send you an email asking you to confirm your free registration. Your privacy is assured and your information is kept confidential. You may unsubscribe at anytime.